245 related articles for article (PubMed ID: 26490985)
1. Patients with chronic lymphocytic leukaemia (CLL) differ in the pattern of CTLA-4 expression on CLL cells: the possible implications for immunotherapy with CTLA-4 blocking antibody.
Ciszak L; Frydecka I; Wolowiec D; Szteblich A; Kosmaczewska A
Tumour Biol; 2016 Mar; 37(3):4143-57. PubMed ID: 26490985
[TBL] [Abstract][Full Text] [Related]
2. Increased expression of CD152 (CTLA-4) by normal T lymphocytes in untreated patients with B-cell chronic lymphocytic leukemia.
Motta M; Rassenti L; Shelvin BJ; Lerner S; Kipps TJ; Keating MJ; Wierda WG
Leukemia; 2005 Oct; 19(10):1788-93. PubMed ID: 16094420
[TBL] [Abstract][Full Text] [Related]
3. The microenvironment differentially impairs passive and active immunotherapy in chronic lymphocytic leukaemia - CXCR4 antagonists as potential adjuvants for monoclonal antibodies.
Buchner M; Brantner P; Stickel N; Prinz G; Burger M; Bär C; Dierks C; Pfeifer D; Ott A; Mertelsmann R; Gribben JG; Veelken H; Zirlik K
Br J Haematol; 2010 Oct; 151(2):167-78. PubMed ID: 20738306
[TBL] [Abstract][Full Text] [Related]
4. Abnormal Expression of BTLA and CTLA-4 Immune Checkpoint Molecules in Chronic Lymphocytic Leukemia Patients.
Karabon L; Partyka A; Ciszak L; Pawlak-Adamska E; Tomkiewicz A; Bojarska-Junak A; Roliński J; Wołowiec D; Wrobel T; Frydecka I; Kosmaczewska A
J Immunol Res; 2020; 2020():6545921. PubMed ID: 32775467
[TBL] [Abstract][Full Text] [Related]
5. Leukaemic cells from chronic lymphocytic leukaemia patients undergo apoptosis following microtubule depolymerization and Lyn inhibition by nocodazole.
Frezzato F; Trimarco V; Martini V; Gattazzo C; Ave E; Visentin A; Cabrelle A; Olivieri V; Zambello R; Facco M; Zonta F; Cristiani A; Brunati AM; Moro S; Semenzato G; Trentin L
Br J Haematol; 2014 Jun; 165(5):659-72. PubMed ID: 24606526
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the in vitro effects of the anti-CD20 antibodies rituximab and GA101 on chronic lymphocytic leukaemia cells.
Patz M; Isaeva P; Forcob N; Müller B; Frenzel LP; Wendtner CM; Klein C; Umana P; Hallek M; Krause G
Br J Haematol; 2011 Feb; 152(3):295-306. PubMed ID: 21155758
[TBL] [Abstract][Full Text] [Related]
7. The potential anticancer agent PK11195 induces apoptosis irrespective of p53 and ATM status in chronic lymphocytic leukemia cells.
Santidrián AF; Cosialls AM; Coll-Mulet L; Iglesias-Serret D; de Frias M; González-Gironès DM; Campàs C; Domingo A; Pons G; Gil J
Haematologica; 2007 Dec; 92(12):1631-8. PubMed ID: 18055986
[TBL] [Abstract][Full Text] [Related]
8. Recombinant human IL-15 trans-presentation by B leukemic cells from chronic lymphocytic leukemia induces autologous NK cell proliferation leading to improved anti-CD20 immunotherapy.
Laprevotte E; Voisin G; Ysebaert L; Klein C; Daugrois C; Laurent G; Fournie JJ; Quillet-Mary A
J Immunol; 2013 Oct; 191(7):3634-40. PubMed ID: 23997218
[TBL] [Abstract][Full Text] [Related]
9. Enhancement of antitumor immunity by combining anti-cytotoxic T lymphocyte antigen-4 antibodies and cryotreated tumor lysate-pulsed dendritic cells in murine osteosarcoma.
Kawano M; Itonaga I; Iwasaki T; Tsumura H
Oncol Rep; 2013 Mar; 29(3):1001-6. PubMed ID: 23291864
[TBL] [Abstract][Full Text] [Related]
10. Leukemic B Cell CTLA-4 Suppresses Costimulation of T Cells.
Do P; Beckwith KA; Cheney C; Tran M; Beaver L; Griffin BG; Mo X; Liu Y; Lapalombella R; Hertlein E; Muthusamy N; Byrd JC
J Immunol; 2019 May; 202(9):2806-2816. PubMed ID: 30910862
[TBL] [Abstract][Full Text] [Related]
11. Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25.
Hannani D; Vétizou M; Enot D; Rusakiewicz S; Chaput N; Klatzmann D; Desbois M; Jacquelot N; Vimond N; Chouaib S; Mateus C; Allison JP; Ribas A; Wolchok JD; Yuan J; Wong P; Postow M; Mackiewicz A; Mackiewicz J; Schadendorff D; Jaeger D; Zörnig I; Hassel J; Korman AJ; Bahjat K; Maio M; Calabro L; Teng MW; Smyth MJ; Eggermont A; Robert C; Kroemer G; Zitvogel L
Cell Res; 2015 Feb; 25(2):208-24. PubMed ID: 25582080
[TBL] [Abstract][Full Text] [Related]
12. Poxvirus-based active immunotherapy synergizes with CTLA-4 blockade to increase survival in a murine tumor model by improving the magnitude and quality of cytotoxic T cells.
Foy SP; Mandl SJ; dela Cruz T; Cote JJ; Gordon EJ; Trent E; Delcayre A; Breitmeyer J; Franzusoff A; Rountree RB
Cancer Immunol Immunother; 2016 May; 65(5):537-49. PubMed ID: 26961085
[TBL] [Abstract][Full Text] [Related]
13. Cytotoxic effects of the trifunctional bispecific antibody FBTA05 in ex-vivo cells of chronic lymphocytic leukaemia depend on immune-mediated mechanism.
Boehrer S; Schroeder P; Mueller T; Atz J; Chow KU
Anticancer Drugs; 2011 Jul; 22(6):519-30. PubMed ID: 21637160
[TBL] [Abstract][Full Text] [Related]
14. Ofatumumab capacity to deplete B cells from chronic lymphocytic leukaemia is affected by C4 complement exhaustion.
Tempescul A; Bagacean C; Riou C; Bendaoud B; Hillion S; Debant M; Buors C; Berthou C; Renaudineau Y
Eur J Haematol; 2016 Mar; 96(3):229-35. PubMed ID: 25911969
[TBL] [Abstract][Full Text] [Related]
15. Pro-apoptotic effect of an anti-CD37 scFv-Fc fusion protein, in combination with the anti-CD20 antibody, ofatumumab, on tumour cells from B-cell malignancies.
Smolewski P; Robak P; Cebula-Obrzut B; Misiewicz M; Mędra A; Majchrzak A; Witkowska M; Stromatt S; Robak T
Eur J Cancer; 2014 Oct; 50(15):2677-84. PubMed ID: 25154027
[TBL] [Abstract][Full Text] [Related]
16. Expression and function of the FAS antigen in B chronic lymphocytic leukemia and hairy cell leukemia.
Panayiotidis P; Ganeshaguru K; Foroni L; Hoffbrand AV
Leukemia; 1995 Jul; 9(7):1227-32. PubMed ID: 7543175
[TBL] [Abstract][Full Text] [Related]
17. CTLA-4 affects expression of key cell cycle regulators of G0/G1 phase in neoplastic lymphocytes from patients with chronic lymphocytic leukaemia.
Ciszak L; Frydecka I; Wolowiec D; Szteblich A; Kosmaczewska A
Clin Exp Med; 2016 Aug; 16(3):317-32. PubMed ID: 26003188
[TBL] [Abstract][Full Text] [Related]
18. Release of interleukin-6 in cultured B-chronic lymphocytic leukaemia cells is associated with both activation and cell death via apoptosis.
Büssing A; Stein GM; Stumpf C; Schietzel M
Anticancer Res; 1999; 19(5B):3953-9. PubMed ID: 10628337
[TBL] [Abstract][Full Text] [Related]
19. Ctla-4 blockade plus adoptive T-cell transfer promotes optimal melanoma immunity in mice.
Mahvi DA; Meyers JV; Tatar AJ; Contreras A; Suresh M; Leverson GE; Sen S; Cho CS
J Immunother; 2015; 38(2):54-61. PubMed ID: 25658614
[TBL] [Abstract][Full Text] [Related]
20. Role of CTLA4 in the proliferation and survival of chronic lymphocytic leukemia.
Mittal AK; Chaturvedi NK; Rohlfsen RA; Gupta P; Joshi AD; Hegde GV; Bociek RG; Joshi SS
PLoS One; 2013; 8(8):e70352. PubMed ID: 23936412
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
